PainReform Ltd. 2021 Investor Presentation PRF-110

PainReform Ltd. presents PRF-110, a novel extended-release ropivacaine formulation for post-operative pain management. The company has completed Phase 1 and Phase 2 studies showing pain relief up to 72 hours and received FDA approval to initiate two Phase 3 trials for NDA submission under the 505(b)(2) pathway.